Copays for all Boehringer Ingelheim GmbH inhaler products will be capped at $35 per fill for patients who are commercially insured, underinsured or uninsured beginning June 1 under a new program announced by the company on 7 March.
Now It’s Asthma Inhalers’ Turn: Boehringer Will Cap Copays, Cut Some List Prices As Pressure Grows
Inhalers seem poised to take insulin’s spot as a top punching bag for Rx industry critics. BI’s action, a first among the marketers of inhalers for asthma and COPD, follows challenges from Bernie Sanders and the FTC on the cost of such products.
